Allogene Therapeutics Announces Board and Compensation Changes
Ticker: ALLO · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, director-appointment
Related Tickers: ALLO
TL;DR
Allogene Therapeutics (ALLO) reshuffled its board and updated exec pay on Jan 23.
AI Summary
Allogene Therapeutics, Inc. announced on January 23, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Anthony J. Kim has been appointed as a new director, and the company has entered into new compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can sometimes indicate underlying issues or strategic shifts that may affect the company's future performance.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- Dr. Anthony J. Kim (person) — Newly appointed director
- January 23, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director at Allogene Therapeutics?
Dr. Anthony J. Kim has been appointed as a new director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 23, 2025.
What are the main items covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
In which state was Allogene Therapeutics, Inc. incorporated?
Allogene Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Allogene Therapeutics, Inc.?
The principal executive office is located at 210 East Grand Avenue, South San Francisco, California 94080.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-29 08:35:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ALLO The Nasdaq Stock Mar
Filing Documents
- d932314d8k.htm (8-K) — 22KB
- 0001193125-25-014985.txt ( ) — 137KB
- allo-20250123.xsd (EX-101.SCH) — 3KB
- allo-20250123_lab.xml (EX-101.LAB) — 17KB
- allo-20250123_pre.xml (EX-101.PRE) — 11KB
- d932314d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allogene Therapeutics, Inc. Date: January 29, 2025 By: /s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer